Performance of the Molecular International Prognostic Scoring System (IPSS-M) in Myelodysplastic Syndromes Treated with Hypomethylating Agent-Based Therapy: A Multicenter Analysis
Kelly S. Chien, Rami S. Komrokji(Moffitt Cancer Center), Samuel Urrutia(The University of Texas MD Anderson Cancer Center), Tapan M. Kadia(The University of Texas MD Anderson Cancer Center), Alessia Campagna(Humanitas University), Tareq Abuasab(The University of Texas MD Anderson Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Guillermo Montalban‐Bravo(The University of Texas MD Anderson Cancer Center), David A. Sallman(Moffitt Cancer Center), Koji Sasaki(The University of Texas MD Anderson Cancer Center), Álex Bataller(The University of Texas MD Anderson Cancer Center), Georgina Gener‐Ricos(The University of Texas MD Anderson Cancer Center), Eric Padron(Moffitt Cancer Center), Emmanuel Almanza(The University of Texas MD Anderson Cancer Center), Zhuoer Xie(Mayo Clinic), Mahesh Swaminathan(The University of Texas MD Anderson Cancer Center), Matteo Della Porta(University of Milan), Gautam Borthakur(The University of Texas MD Anderson Cancer Center), Rashmi Kanagal‐Shamanna(The University of Texas MD Anderson Cancer Center), Alexandre Bazinet(The University of Texas MD Anderson Cancer Center), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Sherry Pierce(The University of Texas MD Anderson Cancer Center), Danielle Hammond(The University of Texas MD Anderson Cancer Center), Giulia Maggioni(Humanitas University), Luca Lanino(Humanitas University), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Nicholas J. Short(The University of Texas MD Anderson Cancer Center), Ziyi Li(The University of Texas MD Anderson Cancer Center), Xiao Qin Dong(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center), Najla H. Al Ali(Moffitt Cancer Center), Ahmed Abdelhakeem(The University of Texas MD Anderson Cancer Center)
Cited by 0
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951